Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
You've successfully got advanced quotes worth 5000 HKD
Download APP >>

Trevi Therapeutics (TRVI) Set to Announce Earnings on Thursday

Defense World ·  {{timeTz}}

Trevi Therapeutics (NASDAQ:TRVI – Get Rating) will be releasing its earnings data after the market closes on Thursday, August 11th. Analysts expect Trevi Therapeutics to post earnings of ($0.21) per share for the quarter. Investors that wish to register for the company's conference call can do so using this link.

Trevi Therapeutics (NASDAQ:TRVI – Get Rating) last issued its earnings results on Thursday, May 12th. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.07. During the same period in the previous year, the company earned ($0.43) EPS. On average, analysts expect Trevi Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Get Trevi Therapeutics alerts:

Trevi Therapeutics Stock Performance

Shares of TRVI opened at $4.09 on Wednesday. The business's fifty day simple moving average is $2.99 and its two-hundred day simple moving average is $2.21. The company has a market cap of $158.23 million, a price-to-earnings ratio of -3.03 and a beta of 0.21. The company has a current ratio of 2.32, a quick ratio of 2.32 and a debt-to-equity ratio of 0.67. Trevi Therapeutics has a 12 month low of $0.46 and a 12 month high of $4.68.

Insider Activity

In other news, major shareholder Tpg Gp A, Llc sold 436,431 shares of the firm's stock in a transaction dated Friday, July 1st. The stock was sold at an average price of $2.86, for a total transaction of $1,248,192.66. Following the completion of the transaction, the insider now owns 3,888,452 shares in the company, valued at $11,120,972.72. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold a total of 546,128 shares of company stock worth $1,572,283 over the last 90 days. Corporate insiders own 39.52% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new position in Trevi Therapeutics in the first quarter worth about $44,000. State Street Corp purchased a new position in shares of Trevi Therapeutics during the first quarter valued at approximately $81,000. Finally, Vanguard Group Inc. raised its stake in shares of Trevi Therapeutics by 7.6% during the first quarter. Vanguard Group Inc. now owns 152,831 shares of the company's stock valued at $336,000 after acquiring an additional 10,780 shares in the last quarter. Hedge funds and other institutional investors own 75.34% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently commented on TRVI shares. Needham & Company LLC raised their target price on Trevi Therapeutics from $8.00 to $10.00 and gave the stock a "buy" rating in a report on Wednesday, June 29th. Oppenheimer raised their target price on Trevi Therapeutics to $12.00 in a report on Monday, July 4th.

About Trevi Therapeutics

(Get Rating)

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis.

Featured Stories

  • Get a free copy of the research report on Trevi Therapeutics (TRVI)
  • Are 3M, Honeywell, GE Buys After Quarterly Reports?
  • CVS and Walgreens Show Why Investment Objectives Matter
  • This Defense Stock Has Bullish Fundamentals AND Technicals
  • Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
  • Are Medtronic And Intuitive Surgical Poised For Big Growth?

Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with's FREE daily email newsletter.

Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.

Back to the Top